Intraductal delivery of nanocarriers for ductal carcinomain situtreatment: a strategy to enhance localized delivery / Manisha Pandey, Pung Xiau Wen, Giam Mun Ning, Gan Jia Xing, Liu Man Wei, Dinesh Kumar, Jayashree Mayuren, Mayuren Candasamy, Bapi Gorain, Neha Jain, Gaurav Gupta, Kamal Dua
Ductal carcinomain situdescribes the most commonly occurring, noninvasive malignant breast disease, which could be the leading factor in invasive breast cancer. Despite remarkable advancements in treatment options, poor specificity, low bioavailability and dose-induced toxicity of chemotherapy are the main constraint. A unique characteristic of nanocarriers may overcome these problems. Moreover, the intraductal route of administration serves as an alternative approach. The direct nanodrug delivery into mammary ducts results in the accumulation of anticancer agents at targeted tissue for a prolonged period with high permeability, significantly decreasing the tumor size and improving the survival rate. This review focuses mainly on the intraductal delivery of nanocarriers in treating ductal carcinomain situ, together with potential clinical translational research. in situ in situ Plain language summary Ductal carcinomain situ(DCIS) describes the most commonly occurring, noninvasive malignant breast disease, in which it could be the leading factor to invasive breast cancer. Mammography screening is often the diagnosis method in DCIS. The conventional treatment of DCIS includes breast-conserving surgery, medical treatment, chemotherapy and hormonal therapy. Various approaches are now actively investigated to overcome a number of drawbacks presented in conventional drug-delivery systems. Incorporation of nanocarriers in the drug-delivery system has portrayed certain benefits over the conventional therapy in DCIS where it promotes targeting in tumor cells, in which provision of the maximum therapeutic effects with minimal adverse effects are eventually achieved. With direct intraductal delivery, the drug accumulates at the site of action. Discovery on the intraductal route of administration has also been greatly implemented in managing other diseases. in situ Tweetable abstract Intraductal delivery of chemotherapeutics for the treatment of DCIS avoids systemic toxicity and greater therapeutic response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2023 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pandey, Manisha [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Clinical trial |
|---|
| Umfang: |
1 Online-Ressource (19 p) |
|---|
| doi: |
10.2217/nnm-2022-0234 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011096071 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011096071 | ||
| 003 | DE-627 | ||
| 005 | 20230713210643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2022-0234 |2 doi | |
| 035 | |a (DE-627)KFL011096071 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2022-0234 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Pandey, Manisha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intraductal delivery of nanocarriers for ductal carcinomain situtreatment: a strategy to enhance localized delivery |c Manisha Pandey, Pung Xiau Wen, Giam Mun Ning, Gan Jia Xing, Liu Man Wei, Dinesh Kumar, Jayashree Mayuren, Mayuren Candasamy, Bapi Gorain, Neha Jain, Gaurav Gupta, Kamal Dua |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2023 | |
| 300 | |a 1 Online-Ressource (19 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Ductal carcinomain situdescribes the most commonly occurring, noninvasive malignant breast disease, which could be the leading factor in invasive breast cancer. Despite remarkable advancements in treatment options, poor specificity, low bioavailability and dose-induced toxicity of chemotherapy are the main constraint. A unique characteristic of nanocarriers may overcome these problems. Moreover, the intraductal route of administration serves as an alternative approach. The direct nanodrug delivery into mammary ducts results in the accumulation of anticancer agents at targeted tissue for a prolonged period with high permeability, significantly decreasing the tumor size and improving the survival rate. This review focuses mainly on the intraductal delivery of nanocarriers in treating ductal carcinomain situ, together with potential clinical translational research. in situ in situ Plain language summary Ductal carcinomain situ(DCIS) describes the most commonly occurring, noninvasive malignant breast disease, in which it could be the leading factor to invasive breast cancer. Mammography screening is often the diagnosis method in DCIS. The conventional treatment of DCIS includes breast-conserving surgery, medical treatment, chemotherapy and hormonal therapy. Various approaches are now actively investigated to overcome a number of drawbacks presented in conventional drug-delivery systems. Incorporation of nanocarriers in the drug-delivery system has portrayed certain benefits over the conventional therapy in DCIS where it promotes targeting in tumor cells, in which provision of the maximum therapeutic effects with minimal adverse effects are eventually achieved. With direct intraductal delivery, the drug accumulates at the site of action. Discovery on the intraductal route of administration has also been greatly implemented in managing other diseases. in situ Tweetable abstract Intraductal delivery of chemotherapeutics for the treatment of DCIS avoids systemic toxicity and greater therapeutic response | ||
| 653 | |a clinical trial | ||
| 653 | |a DCIS | ||
| 653 | |a ductal carcinomain situ | ||
| 653 | |a intraductal | ||
| 653 | |a local drug delivery | ||
| 653 | |a nanocarriers | ||
| 653 | |a preclinical studies | ||
| 653 | |a safety | ||
| 653 | |a therapeutic evaluation | ||
| 700 | 1 | |a Wen, Pung Xiau |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Giam Mun |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Gan Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Liu Man |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Dinesh |e verfasserin |4 aut | |
| 700 | 1 | |a Mayuren, Jayashree |e verfasserin |4 aut | |
| 700 | 1 | |a Candasamy, Mayuren |e verfasserin |4 aut | |
| 700 | 1 | |a Gorain, Bapi |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2022-0234 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||